Find a Physician

Return to Pulmonary Hypertension Overview

Clinical Services

Return to Pulmonary Hypertension Overview

Health Information

Return to Pulmonary Hypertension Overview

Research and Clinical Trials

Return to Pulmonary Hypertension Overview

For Patients, Families & Visitors

Return to Pulmonary Hypertension Overview

Professionals

Return to Pulmonary Hypertension Overview

Hospital News

Return to Pulmonary Hypertension Overview

Cardiology

Pulmonary Hypertension

The Pulmonary Hypertension Center is currently participating in several multicenter national and international clinical trials of novel therapeutics for the treatment of pulmonary arterial hypertension, as well as genetic and pharmacogenetic studies to further understand mechanisms of disease and differences in clinical phenotypes of patients with pulmonary hypertension.

• Ambrisentan Pharmacokinetic trial in Children -- a clinical trial designed to assess the pharmaocokinetic properties of ambrisentan (a selective endothelin receptor antagonist) in children with pulmonary arterial hypertension. This medication has been previously approved in adults with pulmonary arterial hypertension, but little is known about its safety and dosing in children. Contact: Erika Berman Rosenzweig, MD
• Ambrisentan in Eisenmenger Syndrome Trial -- a multicenter trial being conducted to evaluate the safety and efficacy of the endothelin receptor antagonist ambrisentan for symptomatic patients with pulmonary hypertension due to the Eisenmenger syndrome. Contact: Erika Berman Rosenzweig, MD
• The REVEAL Registry -- The Pulmonary Hypertension Center is participating in a national registry of patients with various forms of pulmonary arterial hypertension. The registry currently has over 3,400 patients enrolled with the intent of capturing important data to further our understanding of disease and treatment patterns of pulmonary arterial hypertension. Contact: Erika Berman Rosenzweig, MD
• Griphon Study -- an international study of a novel oral prostacyclin receptor agonist for the treatment of symptomatic pulmonary arterial hypertension. Contact: Erika Berman Rosenzweig, MD
• Cicletanine -- a multicenter clinical trial to investigate the use of oral cicletanine for the treatment of adults with symptomatic pulmonary arterial hypertension. Contact: Erika Berman Rosenzweig, MD
• Oral Remodulin -- a multicenter study that will investigate the use of an oral prostanoid, remodulin in patients with symptomatic pulmonary arterial hypertension. Contact: Erika Berman Rosenzweig, MD
• Inhaled Treprostinil Pharmacokinetic Study -- a multicenter trial to determine the pharmacokinetic properties of inhaled treprostinil in patients with pulmonary arterial hypertension on chronic inhaled treprostinil. Contact: Erika Berman Rosenzweig, MD
• Seraphin Trial -- an international study designed to evaluate the safety and efficacy of a novel tissue targeted endothelin receptor antagonist in patients with pulmonary arterial hypertension. Contact: Erika Berman Rosenzweig, MD
• Iloprost in Neonates -- a study to evaluate the safety and efficacy of iloprost, an inhaled prostanoid in neonates suffering from persistent pulmonary hypertension of the newborn. Contact: Erika Berman Rosenzweig, MD
• Dhreams Study -- a multicenter NIH funded study to develop a better understanding of the molecular genetic basis of congenital diaphragmatic hernia (CDH), which is a cause of pulmonary hypertension. The study is designed to identify specific alterations in genes that contribute to CDH through genetic analysis of biological samples from children with CDH and their family members. Contact: Erika Berman Rosenzweig, MD or Wendy Chung, MD, PhD, or visit: www.cdhgenetics.com

Contact

Cardiology

Directions
Clinical Staff: (212) 305-8509